MetaCap

Enliven Therapeutics Inc. (ELVN)

NASDAQ: ELVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

46.53+0.12 (+0.26%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ELVN stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.69
52-week range
14.79 – 62.32
Day range
45.64 – 47.83
Volume / Avg
933.55K / 1.36M
Beta
—

52-week range

$14.79$62.32

ELVN stock today

Enliven Therapeutics (ELVN) closed at $46.53 on Nov 20, up 0.26% (+$0.12), versus the S&P 500's 3.70% decline. Shares are 25.3% below their 52-week high of $62.32, set on Aug 5, 2026 and 214.7% above the 52-week low of $14.79, in the middle of the past year's range. ELVN is up 202.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 113.9%.

Enliven Therapeutics has posted a net loss over the last twelve months (EPS of -$1.69), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Enliven Therapeutics

Company profile

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is based in Burlingame, California.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Richard A. Fair M.B.A.
Headquarters
Burlingame, CA
Employees
65
IPO year
2020

Financial highlights

Full financials

Enliven Therapeutics reported a net loss of $103.7 million, compared with a loss of $89.0 million a year earlier. Diluted earnings per share came in at -$1.83.

Enliven Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-103.69M$-89.02M$-71.58M$-37.66M$-51.38M
EPS (diluted)$-1.83$-1.89$-2.01$-12.05$-2.37

Analyst forecast

Forecast

Consensus (14 analysts)

strong_buy

Avg. price target

$74.33+59.75%

  • Strong buy 3
  • Buy 11
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $69.00High $82.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.36 vs $-0.48
Surprise
+25.00%

ELVN news

All ELVN news

Enliven Therapeutics peers

Health Care sector
ELVN peer companies
CompanyPrice% ChgMarket capCompare
IRONDisc Medicine Inc.75.14-1.27%$3.42Bvs ELVN
VRDNViridian Therapeutics Inc.29.96-4.71%$3.40Bvs ELVN
PBLSParabilis Medicines Inc.27.44-0.67%$3.44Bvs ELVN
AMLXAmylyx Pharmaceuticals Inc.26.02-0.69%$3.35Bvs ELVN
ARQTArcutis Biotherapeutics Inc.26.36-2.98%$3.33Bvs ELVN
XENEXenon Pharmaceuticals Inc.37.04-1.38%$3.64Bvs ELVN
OGNOrganon & Co.13.89-0.14%$3.65Bvs ELVN
ABCLAbCellera Biologics Inc.9.69-7.45%$3.16Bvs ELVN

Indexes, lists and sector

Enliven Therapeutics stock FAQ

What is Enliven Therapeutics's stock price today?

ELVN last traded at $46.53 as of Nov 20, 4:00 PM EST, up 0.26% on the day. Prices are delayed at least 15 minutes.

Who is Enliven Therapeutics's CEO?

Mr. Richard A. Fair M.B.A. is the chief executive officer of Enliven Therapeutics Inc., which has about 65 employees.

What is the ELVN 52-week high?

The 52-week high for ELVN is $62.32 and the 52-week low is $14.79. The stock is currently 25.3% below its high.

Compare ELVN